EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines

The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval, severe allergic reactions to the mRNA‐based vaccines that resolved after treatment were reported. Regulatory agencies from the European Unio...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Allergy (Copenhagen) Ročník 76; číslo 6; s. 1629 - 1639
Hlavní autori:	Sokolowska, Milena, Eiwegger, Thomas, Ollert, Markus, Torres, Maria J., Barber, Domingo, Del Giacco, Stefano, Jutel, Marek, Nadeau, Kari C., Palomares, Oscar, Rabin, Ronald L., Riggioni, Carmen, Vieths, Stefan, Agache, Ioana, Shamji, Mohamed H.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Denmark Blackwell Publishing Ltd 01.06.2021 John Wiley and Sons Inc
Predmet:	Allergens Allergies Anaphylaxis COVID COVID-19 COVID-19 vaccines Diagnosis Dosage Eaaci Position Paper Eaaci Position Papers Immunization Immunogenicity Medical diagnosis mRNA Patients Regulatory agencies SARS‐CoV Vaccines virus
ISSN:	0105-4538, 1398-9995, 1398-9995
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!